Know Cancer

or
forgot password

Phase I Study of Concurrent Selective Lymph Node Late Course Accelerated Hyper-fractionated Radiotherapy and Pemetrexed, Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma


N/A
18 Years
75 Years
Open (Enrolling)
Both
Esophageal Cancer

Thank you

Trial Information

Phase I Study of Concurrent Selective Lymph Node Late Course Accelerated Hyper-fractionated Radiotherapy and Pemetrexed, Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma


Inclusion Criteria:



1. Signed informed consent; 2.Acquired pathological diagnosis; 3.Life expectancy≥6
months; 4.Age:18-75 years, male or female; 5.General state of health: ECOG 0-1 grade;
6.Without any chemotherapy or radiotherapy; 7.Subjects meet the following criteria
for the clinical laboratory:HG≥100g/L, WBC≥3.5X109 /L, neutrophilic
leukocyte≥1.5X109,PLT100X109 /L。CR≤1.5 x N,TB≤2.5XN,AST and ALT≤2.5xN,AKP≤2.5XN.

Exclusion Criteria:

- 1.Serious infection; 2.Uncontrollable diabetes; 3.Other serious diseases, such as
myocardial infarction in 6 months; 4. Participated other clinical trials in 4 weeks
or at present

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Authority:

China: Ethics Committee

Study ID:

phase 1 pem IMRT

NCT ID:

NCT01630174

Start Date:

October 2009

Completion Date:

Related Keywords:

  • Esophageal Cancer
  • IMRT,Pemetrexed,Cisplatin , Esophageal Cancer
  • Carcinoma, Squamous Cell
  • Esophageal Diseases
  • Esophageal Neoplasms

Name

Location